Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?

Date publication

décembre 2022

Journal

Viruses

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent

Tous les auteurs :
Meunier L, Belkacemi M, Pageaux GP, Radenne S, Vallet-Pichard A, Houssel-Debry P, Duvoux C, Botta-Fridlund D, de Ledinghen V, Conti F, Anty R, Di Martino V, Debette-Gratien M, Leroy V, Gerster T, Lebray P, Alric L, Abergel A, Dumortier J, Besch C, Montialoux H, Samuel D, Duclos-Vallée JC, Coilly A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36680177

Résumé

Direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection have been proven safe and effective in cirrhotic patients awaiting liver transplantation (LT). However, in the long term, data remain minimal regarding the clinical impact of viral eradication on patients listed for decompensated cirrhosis or hepatocellular carcinoma (HCC). We aimed to elucidate the clinical outcomes of patients regarding delisting and the evolution of HCC during the long-term follow-up.

Mots clés

DAAs, anti HCV therapy, decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, recurrence after liver transplantation, waiting list

Référence

Viruses. 2022 12 31;15(1):